New eye drug regimen could mean fewer shots for PCV patients
NCT ID NCT07389980
First seen Feb 05, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tests a higher dose of the drug aflibercept (8 mg) given on a personalized schedule to people with a specific eye condition called polypoidal choroidal vasculopathy (PCV), a type of wet macular degeneration. The goal is to see if this approach can safely extend the time between treatments to 16 weeks or longer, reducing the number of injections needed. About 50 adults with untreated PCV will participate, and the study will track vision and eye health over 96 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yeungnam University Hospital
RECRUITINGDaegu, 42415, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.